Uses of benzimidazole derivative for nocturnal acid breakthrough
The present invention relates to a use of benzimidazole derivative compounds for improvement and treatment of nocturnal acid breakthrough (NAB). The benzimidazole derivative compounds can mere effectively prevent and treat gastric acid-related diseases by effectively improving and treating nocturnal nocturnal acid breakthrough symptoms.
1. A method for treating nocturnal acid breakthrough, comprising administering a pharmaceutical composition to a subject in need thereof, wherein the composition comprises a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, as an active ingredient,
2. The method of claim 1 , wherein the composition comprises 10 mg to 500 mg of the compound represented by Chemical Formula 1 or the pharmaceutically acceptable salt thereof.
3. A method for treating nocturnal acid breakthrough, comprising administering a unit dosage form to a subject in need thereof, wherein the unit dosage form comprises 10 mg to 500 mg of a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof,
4. The method of claim 3 , wherein the unit dosage form further comprises a pharmaceutically acceptable carrier.
5. The method of claim 3 , wherein the subject is a patient suffering from a disease selected from the group consisting of erosive gastroesophageal reflux disease (GERD), non-erosive gastroesophageal reflux disease (NERD), gastric ulcer, Barrett's esophagus, and esophagus motility disorder.
6. The method of claim 3 , wherein the unit dosage form alleviates or ameliorates symptoms of heartburn.
7. The method of claim 3 , wherein the unit dosage form is administered before dinner or bedtime.
8. The method of claim 3 , wherein the unit dosage form is administered one to three times a day to a lowest acceptable daily dose.
9. The method of claim 3 , wherein the unit dosage form is a unit dosage form for oral administration.
10. The method of claim 3 , wherein the percentage of time when gastric pH is maintained at 4 or higher out of 12 hours after the administration of the unit dosage form is 65% or more.
11. The method of claim 3 , wherein the gastric pH reaches 4 within 2 hours after the administration of the unit dosage form.
12. The method of claim 1 , wherein the composition comprises 50 mg to 200 mg of the compound represented by Chemical Formula 1 or the pharmaceutically acceptable salt thereof.
13. The method of claim 3 , wherein the unit dosage form comprises 50 mg to 200 mg of the compound represented by Chemical Formula 1 or the pharmaceutically acceptable salt thereof.